Results 21 to 30 of about 10,242 (284)
Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis [PDF]
Investigative and Clinical Urology, 2020 After decades of clinical and basic science research, the clinical application of botulinum toxin A (Botox) in urology has been extended to neurogenic detrusor overactivity (NDO), idiopathic detrusor overactivity, refractory overactive bladder (OAB ...
Jing-Liang Chen , Hann-Chorng Kuo
doaj +1 more source
The positive effect of Botulinum toxin type A on the viability of random flap in tobacco exposed in rats [PDF]
Acta Cirúrgica Brasileira, 2016 PURPOSE: To evaluate the effect of Botulinum Toxin A in different time of tobacco exposure. METHODS: 60 male, Wistar rats were divided into two tobacco exposure groups: a 2- month or a 4-month regimen.
Cristina Pires Camargo +5 more
doaj +2 more sources
Urology Research and Practice, 2023 Objective: This study aimed to evaluate retrospectively the outcomes of Abobotulinumtoxin-A (Dysport®) intravesical injection in refractory interstitial cystitis/ bladder pain syndrome patients to first- and second-line treatment.
Mohammad-Sajjad Rahnamai +4 more
doaj +1 more source
Botulinum Toxin Type a in Cervical Dystonia
International Journal of Immunopathology and Pharmacology, 2012 Cervical dystonia is a syndrome characterized by anomalous postures and unintentional repetitive movements of the head and the neck. Aim of this study is to show the effectiveness of the combined treatment botulinum toxin-FKT through the use of a recent methodic of investigation, myoton, and of the classical clinical evaluations, such as Tsui and VAS ...
Marvulli R. +7 more
openaire +3 more sources
The light chain of tetanus toxin inhibits calcium-dependent vasopressin release from permeabilized nerve endings [PDF]
, 1992 The effects of tetanus toxin and its light and heavy chain subunits on vasopressin release were investigated in digitonin-permeabilized neurosecretory nerve terminals isolated from the neural lobe of the rat pituitary gland.
Weller, U. +5 more
core +1 more source
Toxins, 2022 Improvements in Botulinum toxin type-A (BoNT-A) aesthetic treatments have been jeopardized by the simplistic statement: “BoNT-A treats wrinkles”. BoNT-A monotherapy relating to wrinkles is, at least, questionable.
Alexander D. Nassif +3 more
doaj +1 more source
Botulinum toxin type B micromechanosensor [PDF]
Proceedings of the National Academy of Sciences, 2003 Botulinum neurotoxin (BoNT) types A, B, E, and F are toxic to humans; early and rapid detection is essential for adequate medical treatment. Presently available tests for detection of BoNTs, although sensitive, require hours to days. We report a BoNT-B sensor whose properties allow detection of BoNT-B within minutes.
W, Liu +4 more
openaire +2 more sources
Eurasian Journal of Medicine, 2019 Objective: Body dysmorphic disorder, narcissistic personality disorder, and histrionic personality disorders are the most frequent personality disorders in patients seeking cosmetic interventions.
Alireza Mohebbipour Loron +2 more
doaj +1 more source
Toxins, 2021 The real-world use of onabotulinumtoxinA and incobotulinumtoxinA for cervical dystonia and blepharospasm treatment was assessed in two separate retrospective studies using identical protocols (TRUDOSE and TRUDOSE II). The studies were conducted in Mexico,
Ruth Kent +4 more
doaj +1 more source
Structural analysis of botulinum neurotoxins type B and E by Cryo-EM [Elektronisk resurs]
, 2022 Botulinum neurotoxins (BoNTs) are the causative agents of a potentially lethal paralytic disease targeting cholinergic nerve terminals. Multiple BoNT serotypes exist, with types A, B and E being the main cause of human botulism.
Masuyer, Geoffrey, +5 more
core +2 more sources